Nordicus Partners Corporation reported a net loss of $4.0 million for the fiscal year ending March 31, 2026, compared to a net loss of $2.9 million in the previous year, marking an increase of 38% year-over-year. The company did not generate any revenue during this period, a decline from the $5,000 reported in the prior fiscal year. Operating expenses rose significantly to $4.37 million, up from $2.92 million, driven primarily by increased professional fees related to acquisitions and higher general and administrative costs.
The company has undergone significant strategic changes, including the acquisition of two preclinical-stage biotechnology firms, Orocidin A/S and Bio-Convert A/S, in 2024. These acquisitions were part of Nordicus's strategy to develop therapeutics for oral health issues, specifically targeting periodontitis and oral leukoplakia. In addition, Nordicus formed a new subsidiary, NoviThera ApS, in October 2025, focusing on monoclonal antibody therapy for psoriasis. The company also expanded its board of directors and established several governance committees to enhance its corporate structure.
Operationally, Nordicus's total assets increased to $75.46 million as of March 31, 2026, up from $70.25 million the previous year. The company reported a significant increase in in-process research and development assets, which rose to $45.51 million, reflecting the value of its acquired biotechnology firms. The company’s cash position was $20,878, indicating limited liquidity to support ongoing operations. The total employee headcount and user statistics were not disclosed in the filing.
Looking ahead, Nordicus plans to finance its operations through existing cash reserves and potential private placements of common stock, as it seeks to uplist to the Nasdaq Capital Market. The company has expressed confidence in its strategic direction, particularly with the anticipated start of Phase IIa clinical trials for its lead products in the first half of 2027. However, the company also acknowledged substantial doubt about its ability to continue as a going concern due to its accumulated deficit and lack of revenue generation.
About Nordicus Partners Corp
Nordicus Partners Corporation is a U.S.-listed business accelerator and holding company focused on Nordic life sciences firms. It provides capital, strategic guidance, and operational support to develop innovative biotech companies, advancing drug candidates through early clinical phases. Its portfolio includes preclinical biotech firms targeting treatments for periodontitis and oral leukoplakia, leveraging Nordic innovation and U.S. expertise for market success.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.